---
title: "Repatha (evolocumab) in cardiovascular event risk reduction: Indication questions"
description: "Indication questions on Repatha (evolocumab) in cardiovascular event risk reduction, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Repatha approved for in cardiovascular risk reduction? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/indication"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Repatha (evolocumab) in cardiovascular event risk reduction: Indication questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)

Indication questions that apply to every indication of Repatha are on [Repatha (evolocumab), all indications: Indication](https://www.evicenter.com/medical-information/repatha/indication).

## Indication

<a id="repatha-cv-indication"></a>

### What is Repatha approved for in cardiovascular risk reduction?

> “To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial 
> infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any 
> ischemia-driven arterial revascularization) in adults at increased risk for these events.”

Source: [REPATHA: Prescribing information, page 2, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=2)

Note: The indication statement on the Repatha HCP site, as captured on November 13, 2026, omits "or any ischemia-driven arterial revascularization", which the Prescribing Information revised 10/2026 includes; the Prescribing Information is quoted here.

## Related pages
- [Medical information: Repatha (evolocumab): Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)
- [Clinical trials](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/guidelines)
